Primary Cutaneous Aspergillosis in a Preterm Infant

Pediatr Infect Dis J. 2016 Jun;35(6):704-6. doi: 10.1097/INF.0000000000001136.

Abstract

Primary cutaneous aspergillosis is rare in premature infants. It requires combined medical and surgical strategies. Liposomal amphotericin B is recommended as first-line therapy, but salvage regimens with others antifungal agents, such as voriconazole, have been reported. Voriconazole's pharmacodynamics is unknown in this population. We report a case of severe toxicity to voriconazole in a preterm patient with primary cutaneous aspergillosis.

Publication types

  • Case Reports

MeSH terms

  • Antifungal Agents / administration & dosage
  • Antifungal Agents / adverse effects*
  • Aspergillosis / drug therapy*
  • Dermatomycoses / drug therapy*
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Drug-Related Side Effects and Adverse Reactions / pathology*
  • Fatal Outcome
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Multiple Organ Failure
  • Voriconazole / administration & dosage
  • Voriconazole / adverse effects*

Substances

  • Antifungal Agents
  • Voriconazole